Summit Therapeutics Inc. (SMMT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Summit Therapeutics Inc. (SMMT) closed at USD 15.37 on 2026-10-15, a change of -17.6 % over the past year, with a market capitalization of USD 11.67B.

Summit Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Summit Therapeutics Inc. key figures

Previous close

USD 15.37 (2026-10-15)

1-year change

-17.6 %

Market cap

USD 11.67B

Enterprise value

USD 11B

P/E ratio (trailing)

-13.18

P/E ratio (forward)

-12.50

EPS (trailing)

-1.11

EPS (forward)

-1.17

PEG ratio

n/a

Price to book

18.43

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.51

Employees

265

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Summit Therapeutics Inc. and compare it with other stocks.